Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Butylphthalide in STEMI patients after primary PCI
NCT06704685Phase 3Not yet recruiting
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Dec 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in ST-segment elevation myocardial infarction (STEMI) comparing Butylphthalide group with Placebo group (2 arms). Primary endpoint: Efficacy in reducing myocardial infarct size at 30 days. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
butylphthalide
03
Conditions
ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT06704685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06704685.